CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for York Pharma PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

York Pharma PLC
PO Box 48
Phone: (870) 067-2563p:870 067-2563 Hertfordshire, ENG  SG5 3ZH  United Kingdom Ticker: YRK YRK

This company is no longer actively traded on any major stock exchange.

Business Summary
York Pharma PLC is engaged in the acquisition, development and commercialization of prescription dermatological products along with its subsidiaries. The Company's pipeline comprises 11 products/projects. The products span pre-clinical to pre-registration status, and cover therapeutic areas within prescription dermatology, which include Abasol (dermatomycoses), Sabarep (YP001), YP002 (skin diagnostic), Vampex (YP003), YP004 (skin cancer), YP005 (acne), YP006 (onychomycoses), YP007 (vaginal candidiasis), YP008 (psoriasis), YP009 (cancer) and YP010 (antiviral). York Pharma plc has five operational subsidiaries, York Pharma (R&D) Limited, York Pharma (UK) Limited, York Pharma GmbH, York Pharma KK and Rosanto Pharmaceuticals Limited. In April 2007, the Company announced the acquisition of Rosanto Pharmaceuticals Limited. In November 2007, York Pharma PLC completed the acquisition of Derms Development Limited. In October 2008, the Company acquired Celltran Limited.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20089/30/2007Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board Max D.Bartlett 51 9/22/2005 9/22/2005
Chief Executive Officer, Director Richard J.Anderson 42 1/20/2009 1/20/2009
Chief Financial Officer, Director Ian A.Miscampbell 47 1/20/2009 1/20/2009
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Flammacerium
Flammazine
Rosanto Pharmaceuticals Limited
YRK

General Information
Number of Employees: 23 (As of 9/30/2007)
Outstanding Shares: 61,399,715 (As of 3/2/2009)
Stock Exchange: SEA
Fax Number: (1462) 712-670


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023